Business Wire

Network X 2026 Opens New Chapter in Vienna with Expanded European Focus and Telecom Industry Leaders

4.6.2026 08:00:00 CEST | Business Wire | Press Release

Share

Network X today unveiled the first details of its 2026 edition, marking a major evolution for the international telecoms event as it relocates to Vienna for the first time. Taking place 13-15 October at VIECON, the event will bring together more than 5,500 telecom leaders, operators, infrastructure providers, hyperscalers, policymakers and technology innovators from across Europe and beyond. Registration is now open.

The move to Vienna reflects the growing strategic importance of Central and Eastern Europe in the future of digital infrastructure investment, fibre expansion, data centre networks, AI-enabled mobile networks and next-generation communication services. Austria’s accelerating broadband ambitions and position between Western and Eastern European markets make Vienna a natural fit for the next phase of Network X.

Among the first keynote speakers announced for 2026 are Rudolf Schrefl and Dr. Klaus Steinmaurer, who will join senior leaders from the telecom ecosystem to discuss the future of European network infrastructure, regulation, AI transformation and emerging digital services.

“We are excited to welcome Network X to Austria in 2026,” said Dr. Klaus Steinmaurer, Executive Director Telecommunication and Postal Service, RTR. “At a time of high fibre rollout, this is a critical time for the Austrian telco industry, and Network X is in a unique position to underpinAustria's broadband development goals.”

“Network X 2026 marks a major step forward for the event as we bring the industry to one of Europe’s most strategic locations for fibre CapEx, data centre investment and AI digital infrastructure growth,” said Chris Lycett, Event Director, Network X. “Vienna is the ideal backdrop for deeper collaboration between operators, policymakers, network infrastructure providers and innovators. Our world-class keynote lineup is designed to build stronger industry partnerships and help attendees unlock new business models and accelerate the future of global network monetisation.”

The show is not just relocating - it’s reimagining the programme to align with the evolving needs of the telecom industry as noted by Rudolf Schrefl, CEO, Drei Austria, who said of his session at Network X being “a unique opportunity to discuss the future of telecoms and network infrastructure.”

Furthering the role within the wider digital infrastructure landscape, Data Center World Europe will take place alongside Network X on 13-14 October 2026 at VIECON, bringing together the leading data centre executives to address the challenges and opportunities of powering the data centres of tomorrow. Attendees can select interest for Data Center World Europe as part of the Network X registration.

For more information on the show, visit www.networkxevent.com/.

About Network X

Network X will debut in Vienna on 13-15 October 2026 as the only global event uniting the fixed and mobile telecommunications industries under one roof. Bringing together more than 5,500 senior network infrastructure and service professionals - including 1,500+ operators - the event convenes telecom leaders, technology vendors, policymakers, analysts and media from across the global communications ecosystem. The event is recognised as a critical meeting point for operators and vendors shaping the future of digital infrastructure, enabling attendees to exchange ideas, build strategic partnerships and explore next-generation technologies transforming communications worldwide.

With a focus on advancements in connectivity, AI-driven transformation, and the journey towards full fibre and 6G, Network X provides a comprehensive platform for professionals to learn, engage, and network with experts, technology providers, and peers across the telecommunications landscape. For more information, visit https://networkxevent.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260603151731/en/

Contacts

Media Contact: Suzanne Matulay, networkx@society32.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye